U.S. FDA Issues Action Letter For Sugammadex Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has issued a "not-approvable" letter for sugammadex sodium injection for the reversal of muscle relaxation during general anesthesia.
Source: www.medicalnewstoday.comBioMS Medical Completes Patient Recruitment In Phase III U.S. Multiple Sclerosis Trial BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The trial, named MAESTRO-03, includes approximately 510 patients, and is being conducted at 68 trial sites in the U.S.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
